BP 554 maleate |
| Catalog No.GC15311 |
Selective 5-HT1A agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 82900-57-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BP-554 maleate is a selective agonist of 5-HT1A receptor [1].
The 5-HT1A receptor is a G protein-coupled receptor for endogenous neurotransmitter serotonin (5-HT) and mediates inhibitory neurotransmission.
BP-554 maleate is a selective 5-HT1A receptor agonist. BP-554 showed higher affinity for 5-HT1A receptor than for 5-HT1-non-A, 5-HT2, α2-adrenergic, dopamine D2 and benzodiazepine receptors. In rat hippocampal membranes, BP-554 inhibited the activity of adenylate cyclase stimulated by forskolin [1].
In mice, BP-554 inhibited the accumulation of 5-hydroxytryptophan after decarboxylase inhibition and reduced the concentration of 5-hydroxy-indoleacetic acid in the brain. Also, BP-554 increased the levels of serum corticosterone and induced hypothermia [1]. The 5-HT1(A) receptor, 5-HT, brain-derived neurotrophic factor (BDNF) receptor trkB and BDNF formed an auto/paracrine loop to regulate the serotonergic phenotype. In rats, BP-554 dose-dependently increased amounts of neurons expressing serotonergic markers [2]. In monkeys, injection of BP554 into the primary visual cortex decreased multiunit activity (MUA) without influenced blood oxygen-level-dependent (BOLD) and local field potential (LFP) activity [3].
References:
[1]. Matsuda T, Seong YH, Aono H, et al. Agonist activity of a novel compound, 1-[3-(3,4-methylenedioxyphenoxy)propyl]-4-phenyl piperazine (BP-554), at central 5-HT1A receptors. Eur J Pharmacol, 1989, 170(1-2): 75-82.
[2]. Galter D, Unsicker K. Sequential activation of the 5-HT1(A) serotonin receptor and TrkB induces the serotonergic neuronal phenotype. Mol Cell Neurosci, 2000, 15(5): 446-455.
[3]. Rauch A, Rainer G, Logothetis NK. The effect of a serotonin-induced dissociation between spiking and perisynaptic activity on BOLD functional MRI. Proc Natl Acad Sci U S A, 2008, 105(18): 6759-6764.
| Cas No. | 82900-57-0 | SDF | |
| Chemical Name | 1-(3-(benzo[d][1,3]dioxol-5-yloxy)propyl)-4-phenylpiperazine maleate | ||
| Canonical SMILES | O=C(O)/C([H])=C([H])\C(O)=O.C1(N2CCN(CC2)CCCOC3=CC4=C(OCO4)C=C3)=CC=CC=C1 | ||
| Formula | C20H24N2O3.C4H4O4 | M.Wt | 456.48 |
| Solubility | <45.65mg/ml in DMSO | Storage | Store at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1907 mL | 10.9534 mL | 21.9068 mL |
| 5 mM | 0.4381 mL | 2.1907 mL | 4.3814 mL |
| 10 mM | 0.2191 mL | 1.0953 mL | 2.1907 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *